NR
ALNY icon

Newfound Research’s Alnylam Pharmaceuticals ALNY Stock Holding History

Newfound Research’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-210
Closed -$31K – 128
2020
Q3 		$31K Buy
+210
New +$29.8K 0.09% 76

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Newfound Research's ALNY Position: Q4 2020 in Review

Newfound Research sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2020, closing a stake of 210 shares — an estimated $31K sold.

Newfound Research first reported a position in ALNY in Q3 2020 and held it in 1 quarter. The position peaked at $31K in Q3 2020. 376 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

  • Newfound Research reported no remaining Alnylam Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Newfound Research sold 210 Alnylam Pharmaceuticals shares in Q4 2020, an estimated $31K.
  • Newfound Research first reported a position in Alnylam Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Newfound Research's Alnylam Pharmaceuticals position peaked at $31K in Q3 2020.
  • 376 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on Newfound Research's 13F filing for Q4 2020, filed 22 Jan 2021.